CD274 and gastric cancer: Similarly, in the phase III KEYNOTE-061 trial, pembrolizumab monotherapy for PD-L1 resulted in a Combined Positive Score (CPS) ≥5 for patients with advanced GC or gastroesophageal junction cancer (GEJC) that significantly prolonged the median overall survival (OS) compared to paclitaxel alone (10.4 months vs 8.3 months, respectively), and in patients with PD-L1 CPS≥10, the 24-month survival rate was significantly higher (32.1 % vs 10.9 %) [15].